NCT03330249View on ClinicalTrials.gov

Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion

PHASE2CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

December 3, 2015

Primary Completion Date

May 10, 2021

Study Completion Date

May 10, 2021

Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
DRUG

Split Cisplatin

25 mg/m2/day IV infusion at D1 to D4, at D22 to D25, at D43 to D46 during the radiotherapy.

DRUG

Cisplatin

100 mg/m2/day IV infusion at D1, D22 and D43 during the radiotherapy.

RADIATION

Radiotherapy

70 Gy in 35 fractions of 2 Gy in non-operated patients and 66 Gy in 33 fractions in post-operative.

Trial Locations (1)

67065

Centre Paul Strauss, Strasbourg

All Listed Sponsors
lead

Groupe Oncologie Radiotherapie Tete et Cou

OTHER

NCT03330249 - Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion | Biotech Hunter | Biotech Hunter